Muzastotug (ADG126: masked anti-CTLA-4 Ab) — Topline data
1H 2027
Enrollment into the randomized Phase 2 trial is well on-track, and results are expected in 1H 2027.Source filing
ADAG biotech catalysts & pipeline
ADAGENE INC · Data as of 2026-09-08
ADAGENE INC · Data as of 2026-09-08
1H 2027
Enrollment into the randomized Phase 2 trial is well on-track, and results are expected in 1H 2027.Source filing